Dated: Jun 02, 2023
Publication Name: Clinical Cancer Research
Citations : Preclinical Characterization and Phase 1 Trial Results of INBRX-109, a Third-Generation, Recombinant, Humanized, Death Receptor 5 Agonist Antibody, in Chondrosarcoma
Purpose: Patients with unresectable/metastatic chondrosarcoma have poor prognoses; conventional chondrosarcoma is associated with a median progression-free survival (PFS) of <4 months after first-line chemotherapy. No standard targeted therapies are available. We present the preclinical characterization of INBRX-109, a third-generation death receptor 5 (DR5) agonist, and clinical findings from a phase 1 trial of INBRX-109 in unresectable/metastatic chondrosarcoma (NCT03715933).
Contributors: Vivek Subbiah, Sant P. Chawla, Anthony P. Conley, Breelyn A. Wilky, Anthony Tolcher, Nehal J. Lakhani, David Berz, Vasily Andrianov, William Crago, Monica Holcomb, Abrahim Hussain, Carson Veldstra, James Kalabus, Brianne O’Neill, Lane Senne, Emily Rowell, Analeah B. Heidt, Katelyn M. Willis, Brendan P. Eckelman